Review of thalidomide use in the pediatric population  

Oleh:

Yang, Catherine S. ; Kim, Changhyun ; Antaya, Richard J.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: JAAD: Journal of the American Academy of Dermatology (keterangan: ada di ClinicalKey) vol. 72 no. 04 (Apr. 2015), page 703-711.
Topik: aphthous ulcers; Behçet disease; epidermolysis bullosa pruriginosa; graft-versus-host disease; medical dermatology; pediatrics; peripheral neuropathy; pharmacology; thalidomide

Ketersediaan

Perpustakaan FK Nomor Panggil: J15.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Thalidomide is resurging in the management of adult rheumatologic skin conditions, especially lupus erythematosus. Although use in pediatric patients is reported since the 1990s, there are no systematic reviews describing treatment in children. Thalidomide has immunomodulatory and anti–tumor necrosis factor-a effects as well as antiangiogenic properties, making it useful for a broad spectrum of inflammatory disorders. Thalidomide is second-line treatment for aphthous stomatitis and chronic graft-versus-host disease in children and has been prescribed for many other conditions including actinic prurigo and epidermolysis bullosa pruriginosa. Systemic lupus erythematosus may be less responsive to thalidomide in children than adults. Peripheral neuropathy is observed in both idiosyncratic and dose-dependent relationships; children older than 12 years may be more susceptible to developing this adverse effect than younger patients. There are rare reports of thrombotic complications in children treated for nonmalignant indications. We review the mechanism of action and propose that thalidomide is an alternative treatment for patients who fail or have contraindications to anti–tumor necrosis factor-a biologics.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali